Celyad Oncology Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Matt Kane

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	2.3yrs
Durée moyenne du mandat des membres du conseil d'administration	7.8yrs

Mises à jour récentes de la gestion

Recent updates

We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

Dec 31

PDG

Matt Kane (47 yo)

less than a year

Titularisation

Mr. Matthew R. Kane, also known as Matt, is Chief Executive Officer of Celyad Oncology SA from October 1, 2024. Mr. Kane is the Chief Executive Officer and Director of Tune Therapeutics. Mr. Kane co-founde...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Michel E. Lussier	Co-Founder & Executive Director	no data	€96.31k	0.38% € 156.6k
Matthew Kane	Chief Executive Officer	less than a year	pas de données	pas de données
David Georges	Vice President of Finance & Administration	2.3yrs	pas de données	pas de données
Sara Zelkovic	Communications & Investor Relations Director	no data	pas de données	pas de données
An Phan	Head of Legal	2.3yrs	pas de données	pas de données
Hannes Iserentant	Head of Intellectual Property	2.3yrs	pas de données	pas de données
Eytan Breman	Head of R&D	2.4yrs	pas de données	pas de données
Philippe Dechamps	Corporate Secretary	no data	pas de données	pas de données

2.3yrs

Durée moyenne de l'emploi

48yo

Âge moyen

Gestion expérimentée: L'équipe de direction de CYAD est considérée comme expérimentée (ancienneté moyenne 2.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Michel E. Lussier	Co-Founder & Executive Director	17.8yrs	€96.31k	0.38% € 156.6k
Hilde Windels	Independent Chairwoman of the Board	7.8yrs	€101.10k	pas de données
Serge Goblet	Non-Executive Director	16.8yrs	€15.50k	0.14% € 56.2k
Margo Roberts	Member of Scientific Advisory Board	no data	€10.00k	pas de données
Hinrich Abken	Member of Scientific Advisory Board	8.6yrs	pas de données	pas de données
Marco Davila	Member of Scientific Advisory Board	8.6yrs	pas de données	pas de données
Marina Blagovic	Independent Director	4.5yrs	€49.50k	pas de données
Dominic Piscitelli	Independent Director	4.5yrs	€69.50k	pas de données
Ami Shah	Non-Executive Director	2.9yrs	pas de données	pas de données
Ann Ager	Member of Scientific Advisory Board	no data	pas de données	pas de données
Christopher LiPuma	Non-Executive Director	2.8yrs	pas de données	pas de données
Jean-Christophe Marine	Member of Scientific Advisory Board	no data	pas de données	pas de données

7.8yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de CYAD sont considérés comme expérimentés (ancienneté moyenne 7.8 ans).

Celyad Oncology Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Celyad Oncology Appoints Matt Kane as Chief Executive Officer, Effective October 1, 2024

Celyad Oncology Sa Announces Executive Change

Celyad Oncology SA, Annual General Meeting, May 06, 2024

Less than half of directors are independent

Celyad Oncology SA Announces Chief Financial Officer Changes

Celyad Oncology SA Announces Board Changes

Recent updates

Celyad Oncology Appoints Matt Kane as Chief Executive Officer, Effective October 1, 2024

Celyad Oncology SA to Report First Half, 2025 Results on Sep 25, 2025

Celyad Oncology SA to Report First Half, 2024 Results on Sep 20, 2024

Celyad Oncology SA to Report First Half, 2024 Results on Aug 06, 2024

Celyad Oncology Sa Announces Executive Change

Celyad Oncology SA announced that it has received €9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.

Celyad Oncology SA ADR - Sponsored to Be Deleted from OTC Equity

Celyad Oncology SA, Annual General Meeting, May 06, 2024

Celyad Oncology SA to Report First Half, 2023 Results on Sep 04, 2023

Celyad Oncology SA announced that it expects to receive €9.794 million in funding from Fortress Investment Group LLC, Tolefi S.A., and other investors

Nasdaq to Delist the American Depositary Shares of Celyad Oncology

Celyad Oncology Receives Notification Letter from Nasdaq Regarding ADS's Scheduled for Delisting from The Nasdaq Global Market and to be Suspended at the Opening of U.S. Business on May 19, 2023

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares from Nasdaq

Celyad Oncology Announces Publication of Data from Its Phase 1 Think Study of CYAD-01

Celyad Oncology SA to Report Q1, 2023 Results on May 05, 2023

Celyad Oncology SA to Report Q3, 2023 Results on Nov 09, 2023

Less than half of directors are independent

Celyad Oncology Provides Update on Clinical Trial Programs

Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) for €6 million.

Celyad Oncology Sa Announces Fda Lifts Clinical Hold of Cyad-101-002 Phase 1B Trial

Celyad Oncology SA Announces Chief Financial Officer Changes

Celyad Oncology SA Announces Board Changes

Less than half of directors are independent

Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial

Celyad Oncology SA Announces Voluntary Pause of CYAD-101-002 Phase 1B Trial

Celyad Oncology SA Announces Program Update and Anticipated Milestones for 2022

Celyad Oncology SA Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial

Consensus forecasts updated

Celyad Oncology SA Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition

Celyad Oncology SA announced that it expects to receive €28.73 million in funding from Fortress Investment Group LLC

Forecast to breakeven in 2023

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

Price target decreased to €14.75

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma At the European Hematology Association Virtual Congress

Full year 2020 earnings released: €1.23 loss per share (vs €2.29 loss in FY 2019)

Celyad Oncology SA to Report Fiscal Year 2020 Results on Mar 24, 2021

New 90-day low: €6.42

Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium

Celyad Oncology SA Appoints Marina Udier, Ph.D., to Board of Directors

Celyad Oncology SA announced that it expects to receive $40 million in funding from Lincoln Park Capital, LLC

We're Keeping An Eye On Celyad Oncology's (EBR:CYAD) Cash Burn Rate

Analysts update estimates

Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC

Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma

New 90-day low: €7.64

Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC

New 90-day low: €8.13

New 90-day low - €8.34

Earnings released

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen